Clinical benefits of long-term angiotensin II receptor blockade in patients with severe symptoms of congestive heart failure despite full angiotensin converting enzyme inhibition  by Hamroff, G. et al.
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Interquadllo range 0,09-0,21 mU/mg; p = 0,0019), Thus, in plaques ot pa- 
tients with unstable coronnry syndromes, the higher content of tissue factor 
may be related to the thrombotic response to rupture, 
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~ ATP.aenaltlva Potassium Channel Blockers (KA'tp) 
Suppress Monophealc Action Potential Shortening 
and Abolish the 'Second Window of Protection' 
Induced by Is©heroic Preconditioning In Rabbit 
Hearta 
N,L, Bsmardo, M, D'Angoic, A,B, Jan, M,A, Wood, R,C, Kukrsl~, Oiws~on o1 
C~rrllot(~ly, VCU.Modt¢,'# Colle~ of Vtrglnf~, Rlchmen# VA, USA 
D+lckgrouncl; lschemlc pracondlltontng (PC) brings t~botlt a dohtyod phase 
of myocardial protection 24 hours later, We hypothosG~ed lh~t this 'second 
window of protection' (SWOP) Involves the opening ot K^~[, channels, 
Mofhod,~: Seven groups el rabbits wore sttldl~d using the In Wvo model ot 
myocardial Infarction, t, Control, ~., GIIbonclamlde (G) 9,3 mg/kg IP 30 m+n 
before Iseheml~/reparlusicn (I/R), 3, 5.hydroxydea~noato (~IHD) 5 mgtkg IV 
15 rain before I/R 4, Sh~m operated ~4 hrs prior to I/R, 5, PC • preoondltloned 
with four ~-min cerennPf oocltmions, each separated by 10 rain el repeduslen, 
24 hm before l/R, 6, PC + G, 7, PC .  [~HD, All mbblts undc~ent 30 mln ot 
corona,y occlusion followed by 3 hrs of ropaduslon, Risk area was delineated 
by Ev~n's bhrs dye and Inlamt el~o w~s determined by tetmzollum staining, 
Monopllssie action potential d~lmtlon (APD) was measured by an epicaldlat 
electrode, 
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Resettle: A s~gntttcnnt reduction in inforct sl~o was observed in PC which 
was blocked bv G and 5HD These .~po('.iltc K^r[, channel blockom signifi- 
cantly suppressed APD shortening in PC hearts. 
Corclusion: The 'SWOP' afforded by PC is mediated via the opening of 
K~e channels 
Optimizing Heart Failure Therapy: Latest 
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8~' -  1--~ Irbesartan Comb:ned With Conventional Therapy, 
Including Anglotensln Convertln~ Enzyme 
Inhlbltom, In Heart Failure 
M, Tonkon, N. Awes, I, Niazi, P Henley, L. Bamch, C,-$. Lin, D, Costagliola, 
G, Cucinotta, R.A, Wolf, A.J. Block for the Irbesartan Heart Failure Group. 
Anaheim Heart & Research Institute, Anaheim, CA, USA 
Irbesartan (IRBE; BMS/Sanofi) efficacy and tolorability, combined with con- 
ventional therapy including angiotensln converting enzyme inhibitors (ACE-Is), 
was evaluated in a double-blind, placebo-cantrolle ' (PBO), pilot study of pa- 
tients (pts) with mild-to-moderate heart failure (HF; NYHA Class II or III) 
and left ventricular ejection I:action (LVEF) ~40%, on diuretic ('>2 wks) and 
ACE-I (_-6 wks) therapy. Pts with 2 consistent Modified Naughton exemise 
tolerance tests (ETTs) were randomized to IRBE (n = 57) [starting doses: 
12.5 rag, 37.5 mg, or 75 mg; titrated to 150 mg as tolerated] or PBO (n = 52) 
QD. ACE-I therapy continued. Angiotensin II (All) and plasma resin activity 
(PRA) were studied in 20 pts. Pts were mainly NYHA Class II (79%), male 
(76%), white (82%), with ages equally ~ and <65. 
PRA and All increases were consistent with All receptor blockade. IRBE 
was well tolerated: serious adverse events were rare in both groups; no 
deaths occurred. More PBO pts required supplemental diuretics than did 
IRBE pts (21% vs 12%). 
ETT (soc) LVEF (units) All (pg/mL) PRA (nQ~ml.hr) 
median change moon change 
IRBE 63,5, 2t-t0['  52 (32~7,J) pro: 35, post: 6.9 pro: 0:4, post: 2t,3 
Pad 47,0, - 6-131' 24  ( 0.4-5 t' pro: 0.8, pent'. 2,0 pm 79, post 14 1 
'2r, th-75Ih qunntlles; vskloe in 0 represent I)5% confidence limits. 
Conclusion: IRBE, combined with conventional therapy including ACE.I, 
produced favorable trends in ETT and LVEF and was well tolerated in pfs 
with mlld4c.moderofo HF, 
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~ Angloteneln II Receptor Blockade Combined to 
ACE-Inhibition Improves Loft Ventd©ulsr Ollatlon 
and Exomlae Ejection Fraction In Congestive Heart 
Failure 
M Tecehi, S, Rcennio, A+ An=ulni, A, Sposi, 0, MaftictL G.B Grassl 
Hospital, Rome: HS, R, Milan, Italy; U,P,M.B., Galveston, TX, USA 
Angtotnnsin It type t receptor antagonist Iossrtan (LOS) has recently emerged 
as a valgable alternative to ACE.inhibltors (ACEI) in the manegemonl of con. 
gestivs heart latium (CHF)~ Aim el this study was to determine if the assn. 
ciation of LOS; and ACEI in pts wilh CHF may enhance the wel!.mcegeized 
banefl(~tal effects of ACEI atone on left ventflculsr (LV) dimensions and func- 
tion as assessed by 2D echocardiography at rest and dunng submaximal 
stlpine bicycle exercise (SBE), Seventy.throe pts (74% male, age 64 :t 6 ym) 
with Impaired systolio LV function (EF 28 ~ 9%) and stable mild to moder. 
ate CHF (NYHA (:tess 2, t -t 0.4) were mndomltnd in e double blind fashmn 
to recelvo LOS 50 mg/d (n =, 42) or placebo (P, n ~ 31) in addition to ACEI 
(enslapriL mean dose 29 mg/d or ceptopril, mean dose 86 rag/d) for 3 months. 
All pts were on dlgoxln and diuretics. The two groups were comparable in age, 
goader, El:, LV ond.dlastotie (EDVI) and end.systolic (ESVi) volume inde,, at 
rest and daring SBE. After throe months, both groups showed improved EF 
and LV volumes with respect to values at randomization (p .  091). How. 
evor, treatment with LOS rosulted in significantly greater =mprovement ot LV 
dimensions and function with respect to P, as shown in the Table. 
ACEI * LOS ACEI + P 
At 3 months Rest SBE Rest SBE 
EF (%) 31 t 10" 36 t 129 28 t 12 32 t S 
EOVI (mPm ~) 79 t 13" 71 :t 10 t 87 .t 14 7G ¢ 11 
ESVI (mitre ~) 69 t 10" 58 ~ 8 t ;'2 i 10 66 *. 9 
Mean "~ SD, "p • 0.05 vs ACEI + P Rest: tp. OOS vs ACE + P SBE 
In conclusion, those results indicate that LOS combined to ACEI may 
confer incremental functional benefit as compared to ACEI alone in pts with 
CHF 
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~ '~ Clinical Benefits of Long-term Anglotensin II 
Receptor Blockade in Patients With Severe 
Symptoms of Congestive Heart Failure Despite Full 
Anglotensln Converting Enzyme Inhibition 
G, Hammff, I. Blautarb, D. Mancini, S. Katz, R. Bijou. G. Jondoau, 
M,-T, Olivan. S. Thomas, T. LeJemtol. The Atb~,; C,,ra,,.in College or 
Medicine, Bronx, NY, USA 
Attar initial improvement, symptoms tend to recur in patients with congestive 
heart failure (CHF) despite angiotensin converting enzyme (ACE) inhibition 
at maximally recommended o, tolerated dose, digoxin and loop diuretics. 
The present study was undertaken to determine if the addition of All type 
1 (ATt) receptor blockade to full ACE inhibition would improve functional 
class (FC, NYHA) and maximal exercise capacity (peak VO2, mt/kg/min) in 
patients with severe CHF, i.e. peak VO2 < 16 and FC Ill-IV at baseline (BL). 
Thirty-two patients (mean age 61 yrs, ejection fraction 26%) were randomized 
to placebo (P) or Iosartan (L) 50 mg daily. They were evaluated at 3 and 6 
rodS. Results were as follows: 
BL 3 mes 6 mos 
t. F L P L P 
FC 3,2 3,0 2.9 3.0 2,5" 3.0 
Peak VO2 13.1 14.5 14.7 14.7 15.1" 14.2 
• =p- 0.05Lvs P:L(n = 15);P(n = 14) 
L at a daily dose of 50 mg was well tolerated by all patients. Three 
patients were lost to follow up. In conclusion, long-term ATt receptor blockade 
improves symptoms and exercise capacity in patients with CHF who are 
severely symptomatic despite full ACE inhibition, digitalis and diuretics. 
